WaveMan
WaveMan · Company
CMMB · Chemomab Therapeutics Ltd.
> Search tickers & screens ⌘K
LIVE
← All companies

CMMB Chemomab Therapeutics (CMMB) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001534248
Quote by TradingView
Activist 13DC-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
5
13F, latest reported quarter

What the filings say about CMMB

Insiders, 180 days
+$13.7K net bought
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan
Activist stakes (13D), 180 days
1 filing
Largest: 12.5% of the class

Chemomab Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Chemomab Therapeutics Ltd. insiders bought a net $13.7K of stock across 30 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.

Insider
Filed
Shares
Value
Since filing
Cohen Neil Harris
Director
SELL
2026-09-01 SECtraded 2026-08-28
1,000
$2.8K
-63.4%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (5 buys, 2 sales), the last on Aug 27, 2026.
  • -15.4% median (-15.3% mean) 90-day return after 3 previous buys.
  • The trade is 3.0% of the 33,000 shares held after it.
  • No other insider sold within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Cohen Neil Harris sold about $2.8K of CMMB on Aug 28, 2026; 5 funds added in the latest 13F quarter.
Cohen Neil Harris
Director
SELL
2026-09-01 SECtraded 2026-08-27
1,304
$3.7K
-63.4%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (5 buys, 1 sale), the last on Nov 16, 2022.
  • -15.4% median (-15.3% mean) 90-day return after 3 previous buys.
  • The trade is 3.8% of the 34,000 shares held after it.
  • No other insider sold within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Cohen Neil Harris sold about $3.7K of CMMB on Aug 27, 2026, the largest insider sale at the company since 2023; 5 funds added in the latest 13F quarter.
Mor George Adi
Chief Executive Officer
BUY
2026-06-01 SECtraded 2026-05-29
4,878
$10.0K
-42.5%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jan 3, 2023.
  • The trade is 3.6% of the 134,205 shares held after it.
  • No other insider bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Mor George Adi bought about $10.0K of CMMB on May 29, 2026, the largest insider purchase at the company since 2021; 5 funds added in the latest 13F quarter.
Mor George Adi
Chief Executive Officer
BUY
2026-06-01 SECtraded 2026-05-29
4,926
$10.2K
-42.5%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jan 3, 2023.
  • The trade is 3.5% of the 139,131 shares held after it.
  • No other insider bought within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Mor George Adi bought about $10.2K of CMMB on May 29, 2026, the largest insider purchase at the company since 2021; 5 funds added in the latest 13F quarter.
OrbiMed Israel BioFund GP Limited Partnership
SELL
2023-01-05 SECtraded 2023-01-03
70,524
$318.1K
-88.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 3.1% of the 2,241,274 shares held after it.
  • 1 other insider sold within 30 days.
  • 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider OrbiMed Israel BioFund GP Limited Partnership sold about $318.1K of CMMB on Jan 3, 2023; 1 other insider sold within 30 days and 5 funds added in the latest 13F quarter.
30 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 25 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$13.7K over 180 days
-$6.5K over 90 days
more than 67% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
5 funds bought in last quarter
below 95% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.2% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
the lowest in Pharma & Biotech
The situation: each line is one rule over one dataset
HBM Healthcare Investments (Cayman) Ltd. disclosed a 5%+ stake (12.5%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CMMB

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-65.6%12M
-66%-40%-14%+12%2025-102025-122026-022026-042026-062026-082026-10 2026-05-29 · Mor George Adi bought $10.2K2026-05-29 · Mor George Adi bought $10.0K2026-08-27 · Cohen Neil Harris sold $3.7K2026-08-28 · Cohen Neil Harris sold $2.8K2026-07-16 · HBM Healthcare Investments (Cayman) Ltd. filed a 5%+ stake (12.5%)
Insider buyInsider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CMMB: institutional holders (13F)

13F holdings, latest reported quarter
CITADEL ADVISORS LLC
95,311 sh
$154.4K
ADAR1 Capital Management, LLC
80,000 sh
$129.6K
KESTRA PRIVATE WEALTH SERVICES, LLC
61,710 sh
$100.0K
Ikarian Capital, LLC
51,793 sh
$83.9K
RHUMBLINE ADVISERS
30,529 sh
$49.5K

Congress trades in CMMB

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
HBM Healthcare Investments (Cayman) Ltd.
Activist 13D · 2026-07-16
12.5%

CMMB planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $13.7K bought by insiders over 180 days, 5 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CMMB financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$25.7M
operating cash flow minus capex, 2022-07-01 to 2023-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no debt line filed
FCF yield
-4.5%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$112.0M-$103.0Mn/an/a
Net income-$9.0M-$13.9M-$24.2M-$27.6M
EPS (diluted)0.020.040.100.12
Operating cash flow-$11.1M-$15.4M-$23.6M-$20.4M
Cash$7.6M$6.1M$9.3M$13.5M
SEC XBRL, fiscal years, as known on 2026-10-28

CMMB Stock Sonar score 3/7 axes

Find similar shapesCompare

CMMB ranks highest on risk and compliance (91st percentile) and insider conviction (61st), and lowest on institutional and government (5th), among Pharma & Biotech peers.

Insider conviction
61
Inputs
  • Net Form 4 buying (codes P and S), 180d$14K · 66 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
5
Inputs
  • Funds adding, latest quarter5 · 5 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
91
Inputs
  • Short interest, % of float+0.2% · 91 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Financial health, Growth, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CMMB filings, in plain words

Are Chemomab Therapeutics insiders buying or selling CMMB?

In the 180 days to 2026-10-28, Chemomab Therapeutics insiders were net buyers, a net $13.7K: $20.2K of purchases and $6.5K of sales reported on Form 4, by 1 buyer and 1 seller.

Read the full summary

In the 180 days to 2026-10-28, Chemomab Therapeutics insiders were net buyers of CMMB, a net $13.7K across purchases and sales reported on Form 4 by 1 buyer and 1 seller. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 12.5% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies